This article was taken from Pharmafile Summer 2022, page 22. Samedan Ltd
Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery
This Might Also Be of Interest
![](https://aptar.com/wp-content/uploads/2022/04/AptarPharmaScientificPublications_Icon.jpg)
Leachables Assessment: New pMDI with Low-GWP Propellants
Publications, Pharmaceutical, Brand Differentiation, Market Insights, Product Solutions, Sustainability, Device Innovations
![](https://aptar.com/wp-content/uploads/2022/04/AptarPharmaScientificPublications_Icon.jpg)
Performance of Low-GWP Propellants in pMDIs: Filling and Dose Evaluation
Publications, Pharmaceutical, Sustainability, Device Innovations, Market Insights, Product Solutions
![](https://aptar.com/wp-content/uploads/2022/04/AptarPharmaScientificPublications_Icon.jpg)
Orally Inhaled Drug products; Bioequivalence Models
Publications, Pharmaceutical, Product Solutions, Device Innovations, Brand Differentiation, Market Insights
![](https://aptar.com/wp-content/uploads/2022/04/ConversationsWithAnAptarPharmaExpert.jpg)
Navigating the Development for Orally Inhaled and Nasal Drug Products
Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions